Similarly, sEH inhibitor t-TUCB also lowered portal hypertension in cirrhotic rats by ameliorating endothelial dysfunction and liver fibrosis, which was primarily due to the inhibition of HSC activation and NF-κB signaling by EETs [152] (Figure 8). The gene discussed is EPHX2; the disease is Hepatic fibrosis.